Psychedelics
UCSF researchers test LSD-based MM120 for generalized anxiety disorder
AI에 의해 보고됨 AI에 의해 생성된 이미지 사실 확인됨
UCSF neuroscientist Jennifer Mitchell and collaborators are evaluating MM120, a pharmaceutical form of LSD, as a potential treatment for generalized anxiety disorder. A randomized clinical trial published in JAMA found that a single dose reduced anxiety symptoms versus placebo, with benefits persisting up to 12 weeks in the optimal dose group, according to the study and the drug’s sponsor.
President Donald Trump signed an executive order on Saturday directing federal agencies to accelerate access to psychedelic drugs like psilocybin and ibogaine for treating mental health conditions, including depression, anxiety, and PTSD. The order allocates $50 million in funding and instructs the FDA to prioritize reviews. Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr., Dr. Mehmet Oz, former Navy SEAL Marcus Luttrell, and podcast host Joe Rogan.
AI에 의해 보고됨
Scientists at the Weizmann Institute of Science in Israel have modified tobacco plants to produce five powerful psychedelic compounds typically found in mushrooms, plants, and toads. The technique uses temporary genetic changes to create a sustainable source for research and potential medicines. Experts say this could simplify production compared to chemical synthesis or harvesting from nature.